This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perron, L.
Right arrow Articles by Meyer, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perron, L.
Right arrow Articles by Meyer, F.
Related Collections
Right arrow Screening tests
Right arrow Prostate Cancer
CMAJ • March 5, 2002; 166 (5)
© 2002 Canadian Medical Association or its licensors

Research
Recherche

PSA screening and prostate cancer mortality

Linda Perron*{dagger}, Lynne Moore*, Isabelle Bairati*{dagger}, Paul-Marie Bernard{dagger} and François Meyer*{dagger}

From *the Centre de recherche en cancérologie de l'Université Laval and {dagger}the Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Quebec City, Que.

Correspondence to: Dr. François Meyer, Centre de recherche en cancérologie de l'Université Laval, CHUQ, L'Hôtel-Dieu de Québec, 11 côte du Palais, Québec QC G1R 2J6; fax 418 691-5562; francois.meyer{at}crhdq.ulaval.ca

Background: Physicians have speculated that prostate-specific antigen (PSA) screening may be responsible for the reduction in prostate cancer mortality observed in the late 1990s. In order to test this hypothesis, we assessed the relation between the change in prostate cancer incidence in the early 1990s, attributed largely to PSA screening, and the subsequent change in prostate cancer mortality.

Methods: We divided the adult male population of Quebec aged 50 years and more into 15 birth cohorts. For each birth cohort, we computed the change in prostate cancer incidence between 1989 and 1993 and the change in prostate cancer mortality between 1995 and 1999. We then assessed the correlation between the changes in prostate cancer incidence and the subsequent changes in prostate cancer mortality by weighted linear regression. We also split up the study population into 15 regional populations and repeated the analysis described above.

Results: We found that even though most birth cohorts showed an increase in prostate cancer incidence and a subsequent decrease in mortality, the sizes of these changes were not inversely correlated (Pearson's r = 0.33, 1-sided p = 0.89). Similarly, in the regional population study, we found that a greater increase in prostate cancer incidence did not indicate a greater decline in mortality (Pearson's r = 0.13, 1-sided p = 0.68).

Interpretation: These results suggest that for our study population PSA screening was not associated with, and therefore cannot explain, the decline in prostate cancer mortality.




This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
C. Hamashima, T. Nakayama, M. Sagawa, H. Saito, and T. Sobue
The Japanese Guideline for Prostate Cancer Screening
Jpn. J. Clin. Oncol., June 1, 2009; 39(6): 339 - 351.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. C. Albertsen
The Prostate Cancer Conundrum
J Natl Cancer Inst, July 2, 2003; 95(13): 930 - 931.
[Full Text] [PDF]

Home page
 CMAJHome page
A. J. Coldman, N. Phillips, and T. A. Pickles
Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity
Can. Med. Assoc. J., January 7, 2003; 168(1): 31 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
L. Berlin
Liability for Failure to Order Screening Examinations
Am. J. Roentgenol., December 1, 2002; 179(6): 1401 - 1405.
[Full Text] [PDF]

Home page
 CMAJHome page
M. McGregor
PSA screening: correlating noise with noise?
Can. Med. Assoc. J., August 1, 2002; 167(4): 340 - 340.
[Full Text] [PDF]

Home page
 CMAJHome page
L. Perron, L. Moore, I. Bairati, F. Meyer, and P.-M. Bernard
PSA screening: correlating noise with noise?
Can. Med. Assoc. J., August 1, 2002; 167(4): 340 - 340.
[Full Text] [PDF]

Home page
 CMAJHome page
F. Labrie and B. Candas
Interpreting the Quebec prostate cancer study
Can. Med. Assoc. J., August 1, 2002; 167(4): 340 - 340.
[Full Text] [PDF]

Home page
 CMAJHome page
A. N. Vis
Does PSA screening reduce prostate cancer mortality?
Can. Med. Assoc. J., March 1, 2002; 166(5): 600 - 601.
[Full Text] [PDF]